130 related articles for article (PubMed ID: 17293390)
1. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
[No Abstract] [Full Text] [Related]
2. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
[TBL] [Abstract][Full Text] [Related]
3. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
[TBL] [Abstract][Full Text] [Related]
4. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
Bernet L; Martinez Benaclocha M; Castera C; Cano Muñoz R; Sevilla F; Alba J; de Dios Barranco J; Cordoba A; Garcia-Caballero T; Hardisson D; de Francisco Hernandez JM; Lazaro JM; Polo L; Riu F; Rezola R; Rojo F; Ruiz I; Hernándiz A; de la Cámara de Las Heras JM; Coupe VM
Diagn Mol Pathol; 2012 Jun; 21(2):84-92. PubMed ID: 22555091
[TBL] [Abstract][Full Text] [Related]
5. [HER2 gene amplification assay: is CISH an alternative to FISH?].
Denoux Y; Arnould L; Fiche M; Lannes B; Couturier J; Vincent-Salomon A; Penault-Llorca F; Antoine M; Balaton A; Baranzelli MC; Becette V; Bellocq JP; Bibeau F; Ettore F; Fridman V; Gnassia JP; Jacquemier J; MacGrogan G; Mathieu MC; Migeon C; Rigaud C; Roger P; Sigal-Zafrani B; Simony-Lafontaine J; Trassard M; Treilleux I; Verriele V; Voigt JJ;
Ann Pathol; 2003 Dec; 23(6):617-22. PubMed ID: 15094603
[TBL] [Abstract][Full Text] [Related]
6. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
7. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M; Rasmussen BB
Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
9. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
10. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
12. The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.
Foged NT; Brügmann A; Jørgensen JT
Expert Rev Mol Diagn; 2013 Apr; 13(3):233-42. PubMed ID: 23570400
[TBL] [Abstract][Full Text] [Related]
13. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
15. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
[TBL] [Abstract][Full Text] [Related]
16. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
Gong Y; Sweet W; Duh YJ; Greenfield L; Fang Y; Zhao J; Tarco E; Symmans WF; Isola J; Sneige N
Am J Clin Pathol; 2009 Apr; 131(4):490-7. PubMed ID: 19289584
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis of HER2 gene amplification in breast carcinoma].
Couturier J; Vincent-Salomon A; Mathieu MC; Valent A; Bernheim A
Pathol Biol (Paris); 2008 Sep; 56(6):375-9. PubMed ID: 18456424
[TBL] [Abstract][Full Text] [Related]
18. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.
Reisenbichler ES; Horton D; Rasco M; Andea A; Hameed O
Am J Clin Pathol; 2012 Jan; 137(1):102-10. PubMed ID: 22180483
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.
Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R
Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
